In order to explore the potential of PE to be developed as a multitarget drug to treat insulin resistance and chronic complications associated with T2DM, we have carried out an in-depth study on its inhibitory mechanism, including analysis of the insulin signalling pathway; in parallel, we have evaluated the AR inhibitory activity of PE. This evidence concerns the gene INS and Insulin resistance.